Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, primarily in adult patients.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product is manufactured under EU regulations and meets European pharmacopoeial standards, ensuring consistent potency and purity.

Lenalidomide is used in the management of hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple Myeloma: reduces disease progression and improves survival in adult patients. - Myelodysplastic syndromes with del(5q): corrects ineffective hematopoiesis and reduces transfusion dependence. - Mantle Cell Lymphoma: contributes to tumor control and prolongs remission in eligible adults.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools that may require management.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: significant liver enzyme elevations or liver injury.

Lenalidomide requires careful monitoring and specific safety measures.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: use with caution in severe renal dysfunction and monitor renal function. - Hepatic impairment: monitor liver function tests regularly. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Lenalidomide can interact with several medicines, requiring attention to both major and moderate interactions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): increased risk of thromboembolic events. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - NSAIDs: additive risk of thrombocytopenia. - Live attenuated vaccines: potential reduced efficacy; consider timing of administration.